Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors

Exclusion Criteria

• •Recent radiation therapy for cancer that has spread to bones or to the brain
• •History of a severe reaction to prior immune checkpoint inhibitors
• •Pleural or pericardial effusion, or history of recurrent pleural or pericardial effusion.
• •Heart rhythm with symptoms within the last 12 months
• •Known or suspected intolerance or hypersensitivity to sargramostim or any product component or diluent
• •Use drugs that can suppress the immune system
• •Women who are pregnant or breastfeeding
• •Live virus vaccine within 28 days prior to study treatment and for 4 weeks after study treatment.
• •Have other active cancers
• •Participation in another clinical trial
• •Any other medical condition or laboratory abnormality that would put patient at risk or confound interpretation of trial results